David W. Litchfield
Affiliations: | The University of Western Ontario (Canada) |
Area:
Cell Biology, Biochemistry, Molecular BiologyGoogle:
"David Litchfield"Mean distance: (not calculated yet)
Children
Sign in to add trainee| Greg Vilk | grad student | 2003 | The University of Western Ontario (Canada) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Reinecke M, Brear P, Vornholz L, et al. (2023) Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors. Nature Chemical Biology |
| Lefebvre C, Pellizzari S, Bhat V, et al. (2023) Involvement of the AKT Pathway in Resistance to Erlotinib and Cabozantinib in Triple-Negative Breast Cancer Cell Lines. Biomedicines. 11 |
| Gyenis L, Menyhart D, Cruise ES, et al. (2022) Chemical Genetic Validation of CSNK2 Substrates Using an Inhibitor-Resistant Mutant in Combination with Triple SILAC Quantitative Phosphoproteomics. Frontiers in Molecular Biosciences. 9: 909711 |
| Strum SW, Gyenis L, Litchfield DW. (2021) CSNK2 in cancer: pathophysiology and translational applications. British Journal of Cancer |
| Roffey SE, Litchfield DW. (2021) CK2 Regulation: Perspectives in 2021. Biomedicines. 9 |
| Wells CI, Drewry DH, Pickett JE, et al. (2021) Development of a potent and selective chemical probe for the pleiotropic kinase CK2. Cell Chemical Biology |
| Nouri-Nejad D, O'Donnell BL, Patil CS, et al. (2021) Pannexin 1 mutation found in melanoma tumour reduces phosphorylation, glycosylation, and trafficking of the channel-forming protein. Molecular Biology of the Cell. mbcE19100585 |
| Strum S, Gyenis L, Litchfield DW. (2020) CSNK2 in cancer: Pathophysiology and translational applications. Journal of Clinical Oncology. 38: e15594-e15594 |
| Lefebvre C, Litchfield D, Allan A. (2019) Abstract 1282: Understanding the kinomic contributions to tyrosine kinase inhibitor resistance in triple negative breast cancer Cancer Research. 79: 1282-1282 |
| Bowie LE, Maiuri T, Alpaugh M, et al. (2018) N6-Furfuryladenine is protective in Huntington's disease models by signaling huntingtin phosphorylation. Proceedings of the National Academy of Sciences of the United States of America |